Cite
HARVARD Citation
Wu, J. et al. (2022). Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow‐up of the multicenter, single‐arm, Phase 2 study. International journal of cancer. 150 (6), pp. 984-992. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wu, J. et al. (2022). Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow‐up of the multicenter, single‐arm, Phase 2 study. International journal of cancer. 150 (6), pp. 984-992. [Online].